Zevra (ZVRA) Q3 2026 Earnings Call Transcript

Zevra Therapeutics reported Q3 2026 revenue of $37.8 million, up 45% year over year; U.S. MIPLYFFA revenue was $34.0 million, up 12.6% sequentially and 52% year over year. Net income was $19.2 million, or $0.26 per diluted share, versus a $0.5 million loss a year earlier, while cash and investments totaled $270.9 million at September 30. Management expects to file an MIPLYFFA label-expansion sNDA for infants under 24 months in Q1 2027 and expects a CHMP opinion on arimoclomol in Q4 2026; it also said newly identified patients may put the U.S. NPC market above the prior estimate of 300–350 diagnosed patients.

Analysis

The key debate is whether MIPLYFFA can keep growing after penetrating much of the currently diagnosed pool. The modest quarterly enrollment count alongside strong reported sales makes refill persistence, realized net price, and newly diagnosed patient conversion more important than awareness metrics; website traffic is not yet evidence of a larger treated market. Management’s broader-population thesis is plausible, but claims-based estimates need independent validation before they support a durable valuation premium. More NPC competition could expand diagnosis and awareness while still challenging ZVRA’s share and payer position; combination evidence may differentiate MIPLYFFA, but does not eliminate substitution risk.

Near term (weeks to 1–3 months), the CHMP reexamination is the principal binary catalyst: a favorable opinion could support European access and reduce pipeline discounting; another negative outcome would weaken the global growth narrative. Over 6–18 months, watch whether new diagnoses replenish the funnel, whether the infant sNDA advances on schedule, and whether celiprolol’s FDA discussions translate into an actionable path. The vEDS event threshold creates potentially long and unpredictable timing risk.

Reported profitability overstates operating quality as a signal: the warrant fair-value credit is noncash, while EAP reimbursements fluctuate with order timing. Cash reduces near-term financing risk, but does not establish commercial cash generation; verify cash flow and net sales trends in the 10-Q. Contrarian read: the long-term opportunity may be understated if underdiagnosis is real, but the immediate growth trajectory may be over-extrapolated from launch-era uptake and unverified market expansion.

Key Decisions for Investors

• Avoid chasing ZVRA into the CHMP decision without a clear view of event risk. For investors seeking exposure, consider staged entry after the decision rather than paying ahead for a binary catalyst; a negative opinion would invalidate the near-term European upside case.
• Treat U.S. commercial growth as a funnel test, not an awareness story: monitor quarterly prescription forms, newly diagnosed share, conversion to paid therapy, refills, and net realized price. Reassess the thesis if sales growth weakens while enrollment remains low or payer access deteriorates.
• Keep the infant sNDA and celiprolol out of the base case until regulatory milestones are confirmed. Track the Q1 2027 filing and FDA feedback on retrospective vEDS data; delays or a requirement for additional prospective evidence would push out pipeline value realization.
• Before adding on the market-expansion narrative, verify the underlying claims-data methodology, cash flow from operations, and the 10-Q treatment of warrant valuation. Failure to substantiate a larger diagnosed population—or rising commercial costs without durable sales growth—would argue against a valuation rerating.